In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Medicare coverage for psoriasis drugs depends on the type of Medicare plan you have and the drug your doctor prescribes. But if your doctor considers a drug medically necessary, Medicare may cover it.

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Can-Fite BioPharma (CANF) initiated a pivotal phase 3 psoriasis study of its oral drug Piclidenoson with the U.S. Food and Drug Administration ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

Can-Fite BioPharma initiates pivotal Phase 3 study for psoriasis treatment using oral drug Piclidenoson, targeting moderate to severe cases. Can-Fite BioPharma Ltd. announced the initiation of a ...

Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...